HAEMODIALYSIS MACHINE RETROFIT AND CONTROL INSTALLATION AND USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
First Claim
1. A haemodialysis machine retrofit and control installation, comprising:
- an intake-flow blood glucose sensor, connectable to the blood intake-flow of the haemodialysis machine;
an intake-flow blood glutamine sensor, connectable to the blood intake-flow of the haemodialysis machine;
a return-flow blood glucose sensor, connectable to the blood return-flow of the haemodialysis machine;
a return-flow blood glutamine sensor, connectable to the blood return-flow of the haemodialysis machine;
a dialysate glucose controller for controlling the glucose concentrations in the dialysate;
a dialysate glutamine controller for controlling the glutamine concentrations in the dialysate;
a central control unit, connected to the blood glucose sensors, the blood glutamine sensors, the dialysate glucose controller and to the dialysate glutamine controller for regulating the glucose and glutamine levels in the dialysate to obtain a required blood glucose concentration at the return-flow blood glucose sensor and a required blood glutamine concentration at the return-flow blood glutamine sensor; and
an electroencephalograph (EEG) monitor providing the central control unit with information pertaining to spontaneous electro-cerebral activity to initiate raising of glucose and glutamine levels.
1 Assignment
0 Petitions
Accused Products
Abstract
A haemodialysis machine retrofit and control installation including an intake-flow blood glucose sensor and an intake-flow blood glutamine sensor, a return-flow blood glucose sensor and return-flow blood glutamine sensor, a dialysate glucose- and glutamine controller, a central control unit connected to the blood glucose- and glutamine sensors, the dialysate glucose- and glutamine controllers for regulating the glucose and glutamine levels in the dialysate to obtain required blood-glucose and glutamine concentrations at the return-flow blood glucose- and glutamine sensors and an electroencephalograph (EEG) monitor providing the central control unit with information pertaining to spontaneous electro-cerebral activity to initiate raising of glucose and glutamine levels. Also disclosed is a method of treating a proliferative disorder in a human or animal, by reducing via a retrofitted haemodialysis machine blood-glucose or glutamine concentrations in the human or animal body for a pre-defined period of time.
26 Citations
29 Claims
-
1. A haemodialysis machine retrofit and control installation, comprising:
-
an intake-flow blood glucose sensor, connectable to the blood intake-flow of the haemodialysis machine; an intake-flow blood glutamine sensor, connectable to the blood intake-flow of the haemodialysis machine; a return-flow blood glucose sensor, connectable to the blood return-flow of the haemodialysis machine; a return-flow blood glutamine sensor, connectable to the blood return-flow of the haemodialysis machine; a dialysate glucose controller for controlling the glucose concentrations in the dialysate; a dialysate glutamine controller for controlling the glutamine concentrations in the dialysate; a central control unit, connected to the blood glucose sensors, the blood glutamine sensors, the dialysate glucose controller and to the dialysate glutamine controller for regulating the glucose and glutamine levels in the dialysate to obtain a required blood glucose concentration at the return-flow blood glucose sensor and a required blood glutamine concentration at the return-flow blood glutamine sensor; and an electroencephalograph (EEG) monitor providing the central control unit with information pertaining to spontaneous electro-cerebral activity to initiate raising of glucose and glutamine levels. - View Dependent Claims (2, 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28)
-
-
8. A cerebral glycaemic control module, comprising:
-
an extracorporeal circulation circuit, connectable at one end to cerebral arteries and at another end to cerebral veins of a human or animal body; a blood glucose sensor and a flow rate sensor, connectable to the cerebral artery side of the circulation circuit; a blood glucose sensor and a flow rate sensor, connectable to the cerebral vein side of the circulation circuit; a blood glutamine sensor and a flow rate sensor, connectable to the cerebral artery side of the circulation circuit; a blood glutamine sensor and a flow rate sensor, connectable to the cerebral vein side of the circulation circuit; a blood ketone body sensor and a flow rate sensor, connectable to the cerebral artery side of the circulation circuit; a blood ketone sensor and a flow rate sensor, connectable to the cerebral vein side of the circulation circuit; a pharmaceutical compound infusion module disposed into the extracorporeal circulation circuit; a multi-metabolic energy source infusion module disposed into the extracorporeal circulation circuit; and a central control unit, connected to the glucose sensors, glutamine sensors, ketone body sensors, the flow rate sensors and the infusion modules, for controlling the multi-metabolic energy source infusion module. - View Dependent Claims (9)
-
-
26. A method of treating a proliferative disorder in a human or animal, comprising:
-
isolating the cerebral circulation system of a human or animal body from the rest of the blood circulation system; controlling extracorporeally the glucose concentration in the cerebral circulation system via a new control system to a normal level of between 0.2 μ
mol/g to 0.4 μ
mol/g for a pre-defined period of time still ensuring spontaneous electro-cerebral activity as monitored by electroencephalography (EEG); andcontrolling the glutamine concentration in the cerebral circulation system to a normal level of between 0.1 μ
mol/g to 0.3 μ
mol/g for a pre-defined period of time to maintain spontaneous electro-cerebral activity as monitored by electroencephalography (EEG). - View Dependent Claims (29)
-
Specification